A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Open Access
- 1 July 2013
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 49 (14), 2972-2978
- https://doi.org/10.1016/j.ejca.2013.05.020
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.Journal of Clinical Oncology, 2012
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsClinical Cancer Research, 2012
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyThe Lancet Oncology, 2011
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase InhibitionCancer Research, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- The PARP superfamilyBioEssays, 2004